ID

22211

Description

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00352950

Link

https://clinicaltrials.gov/show/NCT00352950

Keywords

Versions (1)
  1. 5/23/17 5/23/17 -
Uploaded on

May 23, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Oncology NCT00352950

English

Eligibility Oncology NCT00352950

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Oncology NCT00352950
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically- or cytologically-confirmed diagnosis of stage iiib or iv non-small cell lung cancer
Description

Non-Small Cell Lung Carcinoma TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C3258246
received only one prior treatment (not including radiation)
Description

Prior Therapy Single | Therapeutic radiology procedure Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0205171
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0332197
measurable disease per response evaluation criteria in solid tumors group (recist) guidelines
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
life expectancy of ≥ 4 months
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
eastern cooperative oncology group (ecog) performance status of 0 or 1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematologic, renal and hepatic function
Description

Hematologic function | Renal function | Liver function

Data type

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
serum-fasting cholesterol ≤ 300 mg/dl serum-fasting triglycerides ≤ 2.5 x uln exclusion criteria:
Description

Fasting cholesterol level | Serum fasting triglyceride measurement | Exclusion Criteria

Data type

boolean

Alias
UMLS CUI [1]
C1282513
UMLS CUI [2]
C0582824
UMLS CUI [3]
C0680251
brain metastases requiring treatment
Description

Metastatic malignant neoplasm to brain Treatment required for

Data type

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0332121
history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline
Description

Pneumonia, Interstitial | Pulmonary Fibrosis | Interstitial Pneumonia Evidence of | Pulmonary Fibrosis Evidence of

Data type

boolean

Alias
UMLS CUI [1]
C0206061
UMLS CUI [2]
C0034069
UMLS CUI [3,1]
C0206061
UMLS CUI [3,2]
C0332120
UMLS CUI [4,1]
C0034069
UMLS CUI [4,2]
C0332120
systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days before enrollment
Description

Systemic Chemotherapy | Therapeutic radiology procedure Systemic | Hormone Therapy Systemic | Immunotherapy Systemic

Data type

boolean

Alias
UMLS CUI [1]
C1883256
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0205373
UMLS CUI [3,1]
C0279025
UMLS CUI [3,2]
C0205373
UMLS CUI [4,1]
C0021083
UMLS CUI [4,2]
C0205373
prior epidermal growth factor receptor targeting agents with the exception of the small molecule egfr tyrosine kinase inhibitors
Description

Pharmaceutical Preparations Targeting Epidermal Growth Factor Receptor | Small Molecule Epidermal growth factor receptor inhibitor

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1521840
UMLS CUI [1,3]
C0034802
UMLS CUI [2,1]
C1328819
UMLS CUI [2,2]
C1443775
prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short serum half-life (less than 1 week) within 30 days before enrollment, or prior experimental or approved proteins/antibodies with longer serum half-life within 6 weeks before enrollment
Description

Cancer treatment | Investigational New Drugs | Small Molecule Against Neoplasms | Biological Products Serum Half-Life Short | Proteins Serum Half-Life Long | Antibodies Serum Half-Life Long

Data type

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0013230
UMLS CUI [3,1]
C1328819
UMLS CUI [3,2]
C0521124
UMLS CUI [3,3]
C0027651
UMLS CUI [4,1]
C0005522
UMLS CUI [4,2]
C0229671
UMLS CUI [4,3]
C0018517
UMLS CUI [4,4]
C1806781
UMLS CUI [5,1]
C0033684
UMLS CUI [5,2]
C0229671
UMLS CUI [5,3]
C0018517
UMLS CUI [5,4]
C0205166
UMLS CUI [6,1]
C0003241
UMLS CUI [6,2]
C0229671
UMLS CUI [6,3]
C0018517
UMLS CUI [6,4]
C0205166
prior therapy with sirolimus, sirolimus analogs
Description

Sirolimus | Sirolimus Analogs

Data type

boolean

Alias
UMLS CUI [1]
C0072980
UMLS CUI [2,1]
C0072980
UMLS CUI [2,2]
C0243071
immunosuppressive agents within 28 days before enrollment
Description

Immunosuppressive Agents

Data type

boolean

Alias
UMLS CUI [1]
C0021081
Back to the top of the page

Similar models

Eligibility Oncology NCT00352950

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Oncology NCT00352950
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma TNM clinical staging
Item
histologically- or cytologically-confirmed diagnosis of stage iiib or iv non-small cell lung cancer
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Prior Therapy Single | Therapeutic radiology procedure Absent
Item
received only one prior treatment (not including radiation)
boolean
C1514463 (UMLS CUI [1,1])
C0205171 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Measurable Disease
Item
measurable disease per response evaluation criteria in solid tumors group (recist) guidelines
boolean
C1513041 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of ≥ 4 months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Renal function | Liver function
Item
adequate hematologic, renal and hepatic function
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Fasting cholesterol level | Serum fasting triglyceride measurement | Exclusion Criteria
Item
serum-fasting cholesterol ≤ 300 mg/dl serum-fasting triglycerides ≤ 2.5 x uln exclusion criteria:
boolean
C1282513 (UMLS CUI [1])
C0582824 (UMLS CUI [2])
C0680251 (UMLS CUI [3])
Metastatic malignant neoplasm to brain Treatment required for
Item
brain metastases requiring treatment
boolean
C0220650 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
Pneumonia, Interstitial | Pulmonary Fibrosis | Interstitial Pneumonia Evidence of | Pulmonary Fibrosis Evidence of
Item
history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline
boolean
C0206061 (UMLS CUI [1])
C0034069 (UMLS CUI [2])
C0206061 (UMLS CUI [3,1])
C0332120 (UMLS CUI [3,2])
C0034069 (UMLS CUI [4,1])
C0332120 (UMLS CUI [4,2])
Systemic Chemotherapy | Therapeutic radiology procedure Systemic | Hormone Therapy Systemic | Immunotherapy Systemic
Item
systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days before enrollment
boolean
C1883256 (UMLS CUI [1])
C1522449 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0279025 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
C0021083 (UMLS CUI [4,1])
C0205373 (UMLS CUI [4,2])
Pharmaceutical Preparations Targeting Epidermal Growth Factor Receptor | Small Molecule Epidermal growth factor receptor inhibitor
Item
prior epidermal growth factor receptor targeting agents with the exception of the small molecule egfr tyrosine kinase inhibitors
boolean
C0013227 (UMLS CUI [1,1])
C1521840 (UMLS CUI [1,2])
C0034802 (UMLS CUI [1,3])
C1328819 (UMLS CUI [2,1])
C1443775 (UMLS CUI [2,2])
Cancer treatment | Investigational New Drugs | Small Molecule Against Neoplasms | Biological Products Serum Half-Life Short | Proteins Serum Half-Life Long | Antibodies Serum Half-Life Long
Item
prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short serum half-life (less than 1 week) within 30 days before enrollment, or prior experimental or approved proteins/antibodies with longer serum half-life within 6 weeks before enrollment
boolean
C0920425 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C1328819 (UMLS CUI [3,1])
C0521124 (UMLS CUI [3,2])
C0027651 (UMLS CUI [3,3])
C0005522 (UMLS CUI [4,1])
C0229671 (UMLS CUI [4,2])
C0018517 (UMLS CUI [4,3])
C1806781 (UMLS CUI [4,4])
C0033684 (UMLS CUI [5,1])
C0229671 (UMLS CUI [5,2])
C0018517 (UMLS CUI [5,3])
C0205166 (UMLS CUI [5,4])
C0003241 (UMLS CUI [6,1])
C0229671 (UMLS CUI [6,2])
C0018517 (UMLS CUI [6,3])
C0205166 (UMLS CUI [6,4])
Sirolimus | Sirolimus Analogs
Item
prior therapy with sirolimus, sirolimus analogs
boolean
C0072980 (UMLS CUI [1])
C0072980 (UMLS CUI [2,1])
C0243071 (UMLS CUI [2,2])
Immunosuppressive Agents
Item
immunosuppressive agents within 28 days before enrollment
boolean
C0021081 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial